查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1860012

日光性角化症治療：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

Actinic Keratosis Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 118 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球日光性角化病治療市場規模估計為 87.64 億美元，預計到 2031 年將成長至 131.44 億美元，2025 年至 2031 年的複合年成長率為 6.1%。

日光性角化症（AKs 或日光性角化症）是由表皮內異型性角質形成細胞增殖引起的角化過度性斑疹、丘疹或斑塊，其發生是由於長期暴露於紫外線所致。它們最常出現在臉部、嘴唇、耳朵、手背、前臂、頭皮或頸部。

在需求方面，多種成長要素症（AK）治療的發展。人口老化和與紫外線照射相關的生活方式擴大了潛在患者群體，而公共衛生部門日益重視早期檢測和皮膚癌預防，則推動了標準化診斷和即時治療方案的普及。技術創新和製劑研發（例如改良的外用基質、新型動態療法（PDT）載體以及更便捷的給藥方式），以及數位化皮膚科通路的蓬勃發展，為企業拓展產品線和深化市場滲透提供了機會。各公司的年度報告都強調，將PDT和創新型外用處方藥作為差異化策略的商業性重點。

儘管機會顯而易見，但也存在重大風險：許多治療方法集中於病灶部位，可能引起局部刺激，降低患者的接受度和治療依從性。新藥和新器械的研發涉及漫長的測試週期、高昂的研發成本以及監管方面的不確定性。不同市場的報銷機制和器械核准流程差異顯著，可能阻礙高附加價值治療方法的推廣應用。未能維持監管透明度和提供真實世界數據（RWE）可能使企業面臨監管審查，並損害市場信心。

市場需求正轉向「治療+維護」一體化模式，強調低刺激性和高遵守用藥的聯合治療。這推動了醫療設備與處方藥之間以及非處方護膚品與處方管道的整合。關鍵的上游工程投入包括外用和全身用活性藥物成分（API）、光敏劑和動態療法（PDT）載體，以及雷射和光療設備的光學和電子元件。從單線生產能力的角度來看，某些光敏劑和小分子API的合成路線依賴特殊的中間體和催化劑，導致產能擴張前置作業時間較長。高階光學元件集中在少數供應商手中，造成前置作業時間和品管的瓶頸。天然萃取物和輔助成分在規模化生產和標準化方面面臨挑戰。對上游工程投資不足會使企業在需求激增或監管變化期間面臨供不應求和成本波動的風險。

本報告旨在按地區/國家、類型和應用對全球光化性角化病治療市場進行全面分析，重點關注總收入、市場佔有率和主要企業的排名。

本報告以銷售收入為指標，對日光性角化病治療市場規模、估算和預測進行了呈現，以2024年為基準年，並涵蓋了2020年至2031年的歷史數據和預測數據。報告採用定量和定性分析相結合的方法，幫助讀者制定日光性角化病治療業務和成長策略，評估市場競爭情況，分析自身在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • DUSA Pharmaceuticals
  • Novartis
  • Perrigo
  • LEO Pharma
  • Bausch Health
  • Taro Pharmaceutical
  • Galderma（Nestle）
  • Biofrontera
  • Almirall
  • Tolmar Pharmaceutical
  • Biofrontera
  • Novartis
  • Sun Pharmaceutical
  • Photocure ASA

按類型分類的細分市場

  • 破壞性治療
  • 動態療法
  • 外用藥物
  • 其他

應用領域

  • 醫院
  • 診所
  • 其他

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Actinic Keratosis Treatment was estimated to be worth US$ 8764 million in 2024 and is forecast to a readjusted size of US$ 13144 million by 2031 with a CAGR of 6.1% during the forecast period 2025-2031.

Actinic keratosis (AKs or solar keratoses) are keratotic macules, papules, or plaques resulting from the intraepidermal proliferation of atypical keratinocytes in response to prolonged exposure to ultraviolet radiation. It's most commonly found on the face, lips, ears, back of your hands, forearms, scalp or neck.

On the demand side, AK treatment is supported by multiple growth drivers: aging populations and UV-exposure related lifestyles expand the potential patient pool; increased public health emphasis on early detection and skin-cancer prevention encourages adoption of standardized diagnostic and field-treatment approaches. Technological and formulation innovations (improved topical vehicles, novel PDT carriers, and more convenient delivery formats), together with digital dermatology channels, provide firms opportunities for product line extension and deeper market penetration. Company annual reports highlight commercial focus on PDT and innovative topical prescriptions as a differentiation strategy.

Despite clear opportunities, notable risks exist: many treatments are lesion-focused and can cause local irritation that reduces patient acceptance and follow-up; development of new drugs and devices entails long trial timelines, high R&D costs, and regulatory uncertainty; reimbursement frameworks and device approval pathways vary widely by market and may impede adoption of premium therapies. Failure to maintain regulatory transparency and real-world evidence can expose companies to regulatory scrutiny and erode market trust.

Demand is shifting toward an integrated "treat + maintain" model, favoring low-irritation, high-adherence combination regimens, with stronger linkages between devices and prescription drugs and convergence of OTC skincare with prescription channels. Upstream key inputs include APIs for topical/systemic agents, photosensitizers and PDT pharmaceutical carriers, and optical/electronic components for laser/light devices. From a single-line capacity perspective, synthesis routes for certain photosensitizers and small-molecule APIs depend on specialized intermediates and catalysts, requiring lengthy capacity expansion lead times; high-end optical components are concentrated among a few suppliers, creating lead-time and quality control bottlenecks; natural extracts and adjunctive ingredients face scalability and standardization issues. Insufficient upstream investment risks supply shortages and cost volatility when demand spikes or regulations change.

This report aims to provide a comprehensive presentation of the global market for Actinic Keratosis Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Actinic Keratosis Treatment by region & country, by Type, and by Application.

The Actinic Keratosis Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Actinic Keratosis Treatment.

Market Segmentation

By Company

  • DUSA Pharmaceuticals
  • Novartis
  • Perrigo
  • LEO Pharma
  • Bausch Health
  • Taro Pharmaceutical
  • Galderma (Nestle)
  • Biofrontera
  • Almirall
  • Tolmar Pharmaceutical
  • Biofrontera
  • Novartis
  • Sun Pharmaceutical
  • Photocure ASA

Segment by Type

  • Destructive Treatment
  • Photodynamic Therapy
  • Topical Medications
  • Others

Segment by Application

  • Hospital
  • Clinic
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Actinic Keratosis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Actinic Keratosis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Actinic Keratosis Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Actinic Keratosis Treatment Product Introduction
  • 1.2 Global Actinic Keratosis Treatment Market Size Forecast (2020-2031)
  • 1.3 Actinic Keratosis Treatment Market Trends & Drivers
    • 1.3.1 Actinic Keratosis Treatment Industry Trends
    • 1.3.2 Actinic Keratosis Treatment Market Drivers & Opportunity
    • 1.3.3 Actinic Keratosis Treatment Market Challenges
    • 1.3.4 Actinic Keratosis Treatment Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Actinic Keratosis Treatment Players Revenue Ranking (2024)
  • 2.2 Global Actinic Keratosis Treatment Revenue by Company (2020-2025)
  • 2.3 Key Companies Actinic Keratosis Treatment Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Actinic Keratosis Treatment Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Actinic Keratosis Treatment
  • 2.6 Actinic Keratosis Treatment Market Competitive Analysis
    • 2.6.1 Actinic Keratosis Treatment Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Actinic Keratosis Treatment Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Actinic Keratosis Treatment as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Destructive Treatment
    • 3.1.2 Photodynamic Therapy
    • 3.1.3 Topical Medications
    • 3.1.4 Others
  • 3.2 Global Actinic Keratosis Treatment Sales Value by Type
    • 3.2.1 Global Actinic Keratosis Treatment Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Actinic Keratosis Treatment Sales Value, by Type (2020-2031)
    • 3.2.3 Global Actinic Keratosis Treatment Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Hospital
    • 4.1.2 Clinic
    • 4.1.3 Others
  • 4.2 Global Actinic Keratosis Treatment Sales Value by Application
    • 4.2.1 Global Actinic Keratosis Treatment Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Actinic Keratosis Treatment Sales Value, by Application (2020-2031)
    • 4.2.3 Global Actinic Keratosis Treatment Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Actinic Keratosis Treatment Sales Value by Region
    • 5.1.1 Global Actinic Keratosis Treatment Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Actinic Keratosis Treatment Sales Value by Region (2020-2025)
    • 5.1.3 Global Actinic Keratosis Treatment Sales Value by Region (2026-2031)
    • 5.1.4 Global Actinic Keratosis Treatment Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Actinic Keratosis Treatment Sales Value, 2020-2031
    • 5.2.2 North America Actinic Keratosis Treatment Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Actinic Keratosis Treatment Sales Value, 2020-2031
    • 5.3.2 Europe Actinic Keratosis Treatment Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Actinic Keratosis Treatment Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Actinic Keratosis Treatment Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Actinic Keratosis Treatment Sales Value, 2020-2031
    • 5.5.2 South America Actinic Keratosis Treatment Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Actinic Keratosis Treatment Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Actinic Keratosis Treatment Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Actinic Keratosis Treatment Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Actinic Keratosis Treatment Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Actinic Keratosis Treatment Sales Value, 2020-2031
    • 6.3.2 United States Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Actinic Keratosis Treatment Sales Value, 2020-2031
    • 6.4.2 Europe Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Actinic Keratosis Treatment Sales Value, 2020-2031
    • 6.5.2 China Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Actinic Keratosis Treatment Sales Value, 2020-2031
    • 6.6.2 Japan Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Actinic Keratosis Treatment Sales Value, 2020-2031
    • 6.7.2 South Korea Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Actinic Keratosis Treatment Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Actinic Keratosis Treatment Sales Value, 2020-2031
    • 6.9.2 India Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 DUSA Pharmaceuticals
    • 7.1.1 DUSA Pharmaceuticals Profile
    • 7.1.2 DUSA Pharmaceuticals Main Business
    • 7.1.3 DUSA Pharmaceuticals Actinic Keratosis Treatment Products, Services and Solutions
    • 7.1.4 DUSA Pharmaceuticals Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
    • 7.1.5 DUSA Pharmaceuticals Recent Developments
  • 7.2 Novartis
    • 7.2.1 Novartis Profile
    • 7.2.2 Novartis Main Business
    • 7.2.3 Novartis Actinic Keratosis Treatment Products, Services and Solutions
    • 7.2.4 Novartis Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Novartis Recent Developments
  • 7.3 Perrigo
    • 7.3.1 Perrigo Profile
    • 7.3.2 Perrigo Main Business
    • 7.3.3 Perrigo Actinic Keratosis Treatment Products, Services and Solutions
    • 7.3.4 Perrigo Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Perrigo Recent Developments
  • 7.4 LEO Pharma
    • 7.4.1 LEO Pharma Profile
    • 7.4.2 LEO Pharma Main Business
    • 7.4.3 LEO Pharma Actinic Keratosis Treatment Products, Services and Solutions
    • 7.4.4 LEO Pharma Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
    • 7.4.5 LEO Pharma Recent Developments
  • 7.5 Bausch Health
    • 7.5.1 Bausch Health Profile
    • 7.5.2 Bausch Health Main Business
    • 7.5.3 Bausch Health Actinic Keratosis Treatment Products, Services and Solutions
    • 7.5.4 Bausch Health Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Bausch Health Recent Developments
  • 7.6 Taro Pharmaceutical
    • 7.6.1 Taro Pharmaceutical Profile
    • 7.6.2 Taro Pharmaceutical Main Business
    • 7.6.3 Taro Pharmaceutical Actinic Keratosis Treatment Products, Services and Solutions
    • 7.6.4 Taro Pharmaceutical Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Taro Pharmaceutical Recent Developments
  • 7.7 Galderma (Nestle)
    • 7.7.1 Galderma (Nestle) Profile
    • 7.7.2 Galderma (Nestle) Main Business
    • 7.7.3 Galderma (Nestle) Actinic Keratosis Treatment Products, Services and Solutions
    • 7.7.4 Galderma (Nestle) Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Galderma (Nestle) Recent Developments
  • 7.8 Biofrontera
    • 7.8.1 Biofrontera Profile
    • 7.8.2 Biofrontera Main Business
    • 7.8.3 Biofrontera Actinic Keratosis Treatment Products, Services and Solutions
    • 7.8.4 Biofrontera Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Biofrontera Recent Developments
  • 7.9 Almirall
    • 7.9.1 Almirall Profile
    • 7.9.2 Almirall Main Business
    • 7.9.3 Almirall Actinic Keratosis Treatment Products, Services and Solutions
    • 7.9.4 Almirall Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Almirall Recent Developments
  • 7.10 Tolmar Pharmaceutical
    • 7.10.1 Tolmar Pharmaceutical Profile
    • 7.10.2 Tolmar Pharmaceutical Main Business
    • 7.10.3 Tolmar Pharmaceutical Actinic Keratosis Treatment Products, Services and Solutions
    • 7.10.4 Tolmar Pharmaceutical Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Tolmar Pharmaceutical Recent Developments
  • 7.11 Biofrontera
    • 7.11.1 Biofrontera Profile
    • 7.11.2 Biofrontera Main Business
    • 7.11.3 Biofrontera Actinic Keratosis Treatment Products, Services and Solutions
    • 7.11.4 Biofrontera Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Biofrontera Recent Developments
  • 7.12 Novartis
    • 7.12.1 Novartis Profile
    • 7.12.2 Novartis Main Business
    • 7.12.3 Novartis Actinic Keratosis Treatment Products, Services and Solutions
    • 7.12.4 Novartis Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Novartis Recent Developments
  • 7.13 Sun Pharmaceutical
    • 7.13.1 Sun Pharmaceutical Profile
    • 7.13.2 Sun Pharmaceutical Main Business
    • 7.13.3 Sun Pharmaceutical Actinic Keratosis Treatment Products, Services and Solutions
    • 7.13.4 Sun Pharmaceutical Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
    • 7.13.5 Sun Pharmaceutical Recent Developments
  • 7.14 Photocure ASA
    • 7.14.1 Photocure ASA Profile
    • 7.14.2 Photocure ASA Main Business
    • 7.14.3 Photocure ASA Actinic Keratosis Treatment Products, Services and Solutions
    • 7.14.4 Photocure ASA Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
    • 7.14.5 Photocure ASA Recent Developments

8 Industry Chain Analysis

  • 8.1 Actinic Keratosis Treatment Industrial Chain
  • 8.2 Actinic Keratosis Treatment Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Actinic Keratosis Treatment Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Actinic Keratosis Treatment Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Actinic Keratosis Treatment Market Trends
  • Table 2. Actinic Keratosis Treatment Market Drivers & Opportunity
  • Table 3. Actinic Keratosis Treatment Market Challenges
  • Table 4. Actinic Keratosis Treatment Market Restraints
  • Table 5. Global Actinic Keratosis Treatment Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Actinic Keratosis Treatment Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Actinic Keratosis Treatment Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Actinic Keratosis Treatment Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Actinic Keratosis Treatment
  • Table 10. Global Actinic Keratosis Treatment Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Actinic Keratosis Treatment as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Actinic Keratosis Treatment Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Actinic Keratosis Treatment Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Actinic Keratosis Treatment Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Actinic Keratosis Treatment Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Actinic Keratosis Treatment Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Actinic Keratosis Treatment Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Actinic Keratosis Treatment Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Actinic Keratosis Treatment Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Actinic Keratosis Treatment Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Actinic Keratosis Treatment Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Actinic Keratosis Treatment Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Actinic Keratosis Treatment Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Actinic Keratosis Treatment Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Actinic Keratosis Treatment Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Actinic Keratosis Treatment Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Actinic Keratosis Treatment Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Actinic Keratosis Treatment Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Actinic Keratosis Treatment Sales Value, (2026-2031) & (US$ Million)
  • Table 31. DUSA Pharmaceuticals Basic Information List
  • Table 32. DUSA Pharmaceuticals Description and Business Overview
  • Table 33. DUSA Pharmaceuticals Actinic Keratosis Treatment Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Actinic Keratosis Treatment Business of DUSA Pharmaceuticals (2020-2025)
  • Table 35. DUSA Pharmaceuticals Recent Developments
  • Table 36. Novartis Basic Information List
  • Table 37. Novartis Description and Business Overview
  • Table 38. Novartis Actinic Keratosis Treatment Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Actinic Keratosis Treatment Business of Novartis (2020-2025)
  • Table 40. Novartis Recent Developments
  • Table 41. Perrigo Basic Information List
  • Table 42. Perrigo Description and Business Overview
  • Table 43. Perrigo Actinic Keratosis Treatment Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Actinic Keratosis Treatment Business of Perrigo (2020-2025)
  • Table 45. Perrigo Recent Developments
  • Table 46. LEO Pharma Basic Information List
  • Table 47. LEO Pharma Description and Business Overview
  • Table 48. LEO Pharma Actinic Keratosis Treatment Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Actinic Keratosis Treatment Business of LEO Pharma (2020-2025)
  • Table 50. LEO Pharma Recent Developments
  • Table 51. Bausch Health Basic Information List
  • Table 52. Bausch Health Description and Business Overview
  • Table 53. Bausch Health Actinic Keratosis Treatment Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Actinic Keratosis Treatment Business of Bausch Health (2020-2025)
  • Table 55. Bausch Health Recent Developments
  • Table 56. Taro Pharmaceutical Basic Information List
  • Table 57. Taro Pharmaceutical Description and Business Overview
  • Table 58. Taro Pharmaceutical Actinic Keratosis Treatment Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Actinic Keratosis Treatment Business of Taro Pharmaceutical (2020-2025)
  • Table 60. Taro Pharmaceutical Recent Developments
  • Table 61. Galderma (Nestle) Basic Information List
  • Table 62. Galderma (Nestle) Description and Business Overview
  • Table 63. Galderma (Nestle) Actinic Keratosis Treatment Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Actinic Keratosis Treatment Business of Galderma (Nestle) (2020-2025)
  • Table 65. Galderma (Nestle) Recent Developments
  • Table 66. Biofrontera Basic Information List
  • Table 67. Biofrontera Description and Business Overview
  • Table 68. Biofrontera Actinic Keratosis Treatment Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Actinic Keratosis Treatment Business of Biofrontera (2020-2025)
  • Table 70. Biofrontera Recent Developments
  • Table 71. Almirall Basic Information List
  • Table 72. Almirall Description and Business Overview
  • Table 73. Almirall Actinic Keratosis Treatment Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Actinic Keratosis Treatment Business of Almirall (2020-2025)
  • Table 75. Almirall Recent Developments
  • Table 76. Tolmar Pharmaceutical Basic Information List
  • Table 77. Tolmar Pharmaceutical Description and Business Overview
  • Table 78. Tolmar Pharmaceutical Actinic Keratosis Treatment Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Actinic Keratosis Treatment Business of Tolmar Pharmaceutical (2020-2025)
  • Table 80. Tolmar Pharmaceutical Recent Developments
  • Table 81. Biofrontera Basic Information List
  • Table 82. Biofrontera Description and Business Overview
  • Table 83. Biofrontera Actinic Keratosis Treatment Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Actinic Keratosis Treatment Business of Biofrontera (2020-2025)
  • Table 85. Biofrontera Recent Developments
  • Table 86. Novartis Basic Information List
  • Table 87. Novartis Description and Business Overview
  • Table 88. Novartis Actinic Keratosis Treatment Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Actinic Keratosis Treatment Business of Novartis (2020-2025)
  • Table 90. Novartis Recent Developments
  • Table 91. Sun Pharmaceutical Basic Information List
  • Table 92. Sun Pharmaceutical Description and Business Overview
  • Table 93. Sun Pharmaceutical Actinic Keratosis Treatment Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Actinic Keratosis Treatment Business of Sun Pharmaceutical (2020-2025)
  • Table 95. Sun Pharmaceutical Recent Developments
  • Table 96. Photocure ASA Basic Information List
  • Table 97. Photocure ASA Description and Business Overview
  • Table 98. Photocure ASA Actinic Keratosis Treatment Products, Services and Solutions
  • Table 99. Revenue (US$ Million) in Actinic Keratosis Treatment Business of Photocure ASA (2020-2025)
  • Table 100. Photocure ASA Recent Developments
  • Table 101. Key Raw Materials Lists
  • Table 102. Raw Materials Key Suppliers Lists
  • Table 103. Actinic Keratosis Treatment Downstream Customers
  • Table 104. Actinic Keratosis Treatment Distributors List
  • Table 105. Research Programs/Design for This Report
  • Table 106. Key Data Information from Secondary Sources
  • Table 107. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Actinic Keratosis Treatment Product Picture
  • Figure 2. Global Actinic Keratosis Treatment Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Actinic Keratosis Treatment Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Actinic Keratosis Treatment Report Years Considered
  • Figure 5. Global Actinic Keratosis Treatment Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Actinic Keratosis Treatment Revenue in 2024
  • Figure 7. Actinic Keratosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Destructive Treatment Picture
  • Figure 9. Photodynamic Therapy Picture
  • Figure 10. Topical Medications Picture
  • Figure 11. Others Picture
  • Figure 12. Global Actinic Keratosis Treatment Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 13. Global Actinic Keratosis Treatment Sales Value Market Share by Type, 2024 & 2031
  • Figure 14. Product Picture of Hospital
  • Figure 15. Product Picture of Clinic
  • Figure 16. Product Picture of Others
  • Figure 17. Global Actinic Keratosis Treatment Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 18. Global Actinic Keratosis Treatment Sales Value Market Share by Application, 2024 & 2031
  • Figure 19. North America Actinic Keratosis Treatment Sales Value (2020-2031) & (US$ Million)
  • Figure 20. North America Actinic Keratosis Treatment Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Europe Actinic Keratosis Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Europe Actinic Keratosis Treatment Sales Value by Country (%), 2024 VS 2031
  • Figure 23. Asia Pacific Actinic Keratosis Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. Asia Pacific Actinic Keratosis Treatment Sales Value by Region (%), 2024 VS 2031
  • Figure 25. South America Actinic Keratosis Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. South America Actinic Keratosis Treatment Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Middle East & Africa Actinic Keratosis Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. Middle East & Africa Actinic Keratosis Treatment Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Key Countries/Regions Actinic Keratosis Treatment Sales Value (%), (2020-2031)
  • Figure 30. United States Actinic Keratosis Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. United States Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 32. United States Actinic Keratosis Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 33. Europe Actinic Keratosis Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. Europe Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 35. Europe Actinic Keratosis Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 36. China Actinic Keratosis Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. China Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 38. China Actinic Keratosis Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 39. Japan Actinic Keratosis Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. Japan Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 41. Japan Actinic Keratosis Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 42. South Korea Actinic Keratosis Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. South Korea Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 44. South Korea Actinic Keratosis Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 45. Southeast Asia Actinic Keratosis Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. Southeast Asia Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 47. Southeast Asia Actinic Keratosis Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 48. India Actinic Keratosis Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. India Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
  • Figure 50. India Actinic Keratosis Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 51. Actinic Keratosis Treatment Industrial Chain
  • Figure 52. Actinic Keratosis Treatment Manufacturing Cost Structure
  • Figure 53. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 54. Bottom-up and Top-down Approaches for This Report
  • Figure 55. Data Triangulation
  • Figure 56. Key Executives Interviewed